ArticleWorld journal of surgical oncology2026
Integrating single-cell transcriptomics and machine learning to predict breast cancer prognosis and immunotherapy sensitivity: a study based on proliferating T cells.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer, a highly prevalent and heterogeneous malignancy, poses challenges in prognosis and treatment. Emerging evidence links proliferative T cells (Tprolif) to tumor development and progression. This study aims to enhance prognostic accuracy in breast cancer by identifying Tprolif-associated risk genes for molecular subtyping and developing a prognostic model grounded in these subtypes.
methodsSingle-cell RNA sequencing (scRNA-seq) data from breast cancer samples were integrated with bulk RNA-seq data from the TCGA-BRCA and GSE20685 cohorts to define Tprolif-based molecular subtypes. A prognostic risk signature was constructed using 10 classical machine learning algorithms, with the optimal algorithm selected through performance testing and validated across multiple datasets. The expression of key model genes was analyzed, and their impact on breast cancer cell proliferation and migration was examined through in vitro experiments.
resultsThree distinct molecular subtypes were identified, each characterized by unique immune cell infiltration profiles and survival outcomes. Using Tprolif-based subtyping and machine learning, the random survival forest (RSF) algorithm exhibited superior predictive performance, as measured by the C index. Patients with lower risk scores demonstrated a more active immune microenvironment with greater immune cell infiltration. Functional assays revealed that knockdown of MTFR1 and SLC52A2 markedly inhibited breast cancer cell proliferation and migration.
conclusionThis study underscores the pivotal role of Tprolif cells in breast cancer immune heterogeneity and introduces a robust prognostic model for patient stratification. The identification of molecular subtypes and validation of MTFR1 and SLC52A2 as potential therapeutic targets provide crucial insights for personalized cancer treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.